Home・Elenco Azioni・MannKind Corp

MannKind Corp

Aperta

SettoreSettore sanitario

3.96 4.21

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

3.7800000000000002

Massimo

3.88

Metriche Chiave
By Trading Economics
Entrata	-671K -17M
Vendite	-22M 90M
P/E Media del settore	140.5 64.641
EPS	-0.02
Margine di Profitto	-18.431
Dipendenti	591
EBITDA	5M 2.5M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+130.26% upside

Dividendi
By Acuity
Utili prossimi	5 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	353M 1.2B
Apertura precedente	-0.25
Chiusura precedente	3.96

Notizie sul Sentiment di mercato

By Acuity

50%

151 / 340 Classifica in Healthcare

MannKind Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

3 ago 2026, 22:51 UTC

MannKind Corp shares are higher in after-market trading, reflecting momentum since Monday's close amid falling Brent crude oil prices and positive market sentiment.

31 lug 2026, 23:56 UTC

MannKind Corp shares traded lower in after-market hours, retreating from earlier gains. The stock remains near the lower end of its one-month range.

30 lug 2026, 18:41 UTC

Event

News

Wells Fargo raised MannKind's price target to $14.00, contributing to positive momentum. The company also reported favorable Phase 1b study results today.

29 lug 2026, 19:47 UTC

News

Event

MannKind Corp reported positive results from its Phase 1b INFLO-1 study, but shares are trading lower amid broader market uncertainty ahead of the Fed's decision.

28 lug 2026, 21:01 UTC

News

MannKind Corp will report its second quarter 2026 financial results on August 5, 2026. Shares are trading higher in after-market hours.

27 lug 2026, 22:06 UTC

MannKind Corp shares are higher in after-market trading, despite earlier declines. No specific news was identified to explain the price movement.

24 lug 2026, 21:01 UTC

Event

MannKind Corp shares are rising in after-market trading following FDA approval of Furoscix ReadyFlow™ for treating edema in heart failure and chronic kidney disease.

23 lug 2026, 10:36 UTC

MannKind Corp shares are higher in pre-market trading, continuing an upward trend since Wednesday, despite declines in the broader tech sector.

22 lug 2026, 21:01 UTC

MannKind Corp shares are higher in after-market trading, reflecting a gain since Wednesday's close, despite remaining below the 20-day moving average.

21 lug 2026, 22:11 UTC

MannKind Corp shares rose in after-market trading, reflecting a broader rebound in technology stocks and strong interest in semiconductor and AI investments.

Confronto tra pari

Modifica del prezzo

MannKind Corp Previsione

Obiettivo di Prezzo

By TipRanks

130.26% in crescita

Previsioni per 12 mesi

Media 8.75 USD 130.26%

Alto 14 USD

Basso 4.75 USD

Basato su 6 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per MannKind Corp - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

6 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 6 che hanno fornito valutazioni azionarie a MannKind Corp - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

151 / 340 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.